Results 51 to 60 of about 411,749 (186)

Characterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4010-4018, May 2026.
Abstract Aims To evaluate the steady‐state pharmacokinetics (PK) and glucodynamic effects of insulin efsitora alfa (efsitora) over a weekly interval in adults with type 2 diabetes (T2D). Materials and Methods This open‐label, multiple dose, euglycaemic clamp study was conducted in 56 insulin naïve adults with T2D (mean [±SD] age, 61.9 ± 5.98 years ...
Jennifer Leohr, Oliver Klein, Tim Heise, Eric Zijlstra, Juliana M. Bue‐Valleskey, Subha Suriyapperuma, Ryan Jarrett, Douglas James, Micheal Case, David Waters, Edward Pratt, Helle Linnebjerg   +11 more
wiley   +1 more source

Capillary Zone Electrophoresis for the Analysis of Phenolic Preservatives in Plasma and Insulin Formulations Using Salting‐Out Assisted Liquid–Liquid Extraction

ELECTROPHORESIS, Volume 47, Issue 4, Page 308-319, April 2026.
A rapid and reliable SALLE–CZE–UV method was developed for the determination of phenolic preservatives in insulin formulations and human plasma. The approach provides efficient extraction, fast separation (< 6 min), and excellent sensitivity, precision, and recovery, meeting regulatory requirements for accurate quantification.
Meriem Dadouch, Yoann Ladner, Catherine Perrin   +2 more
wiley   +1 more source

Insulin detemir and basal insulin therapy.

, 2020
With the introduction of insulin detemir (Levemir [Novo Nordisk A/S, Bagsvaerd, Denmark]), a long-acting basal insulin analog, it is an opportune moment to reevaluate the use of basal insulin therapy and consider current treatment strategies, including ...
Russell-Jones, DL
core  

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2594-2614, April 2026.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz, Aidan Shulkin, Asmaa Housni, Amélie Roy‐Fleming, Rémi Rabasa‐Lhoret, Jean‐Francois Yale, Michael A. Tsoukas, Tricia M. Peters, Anne‐Sophie Brazeau   +8 more
wiley   +1 more source

Determining the effects of insulin Detemir on endogenous secretion of insulin. [PDF]

, 2020
Type 2 diabetes (T2D) is a long-term metabolic disorder. A pilot trial was designed to investigate the effects of the long acting insulin Detemir on endogenous insulin secretion, to assess use in early T2D care.
Van Noorden, B.A., Knopp, J.L., Holder-Pearson, Lui, Vergeer, S.L., Hardy, A.R., Klenner, J.B., Shaw, Geoff, Chase, Geoff   +7 more
core   +1 more source

Toxicological evaluation of insulin detemir

, 2009
Diabetes mellitus is a disease in which a person has a high blood glucose level as a result of either because the body does not produce enough insulin (Type 1), or because the body cells do not properly respond or resistant to the insulin that is ...
Giray, Belma, Erkekoǧlu, Pinar, Sa̧hin, Gon̈ul̈   +2 more
core   +1 more source

Comparison of pharmacodynamics and pharmacokinetics of ultra‐rapid‐acting insulin aspart and rapid‐acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3002-3010, April 2026.
Abstract Aims To compare the effects of dose reductions of ultra‐rapid‐acting insulin aspart (URA‐IAsp) and rapid‐acting insulin aspart (IAsp) on blood glucose concentrations during continuous moderate‐intensity exercise in people with type 1 diabetes (T1D).
Jason P. Pitt, Alexander Müller, Chloe Nicholas, Olivia M. McCarthy, Othmar Moser, Stephen C. Bain, Harald Sourij, Richard M. Bracken   +7 more
wiley   +1 more source

Cost-effectiveness of insulin analogs from the perspective of the Brazilian public health system

Brazilian Journal of Pharmaceutical Sciences, 2017
Human insulin is provided by the Brazilian Public Health System (BPHS) for the treatment of diabetes, however, legal proceedings to acquire insulin analogs have burdened the BPHS health system.
Maurílio de Souza Cazarim, João Paulo Vilela Rodrigues, Estael Luzia Coelho da Cruz-Cazarim, Lorena Rocha Ayres, Leonardo Régis Leira Pereira   +4 more
doaj   +1 more source

Engineering a Glucose‐Responsive Glucagon Prodrug Through Arginine–Phenylboronic Acid Pendant Modification

Small Science, Volume 6, Issue 3, March 2026.
A single‐molecule glucagon prodrug enables self‐regulated delivery through glucose‐dependent charge modulation. Phenylboronic acid–glucose binding induces aggregation and subcutaneous depot formation at normoglycemia, while glucose depletion restores solubility and triggers glucagon release, providing on‐demand protection against hypoglycemia ...
Emily L. DeWolf, Weike Chen, Bernice Webber, Elizabeth M. Power, Rory Kilmer, Pradeep Kadu, Sijie Xian, Matthew J. Webber   +7 more
wiley   +1 more source

Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus

, 2015
ObjectiveWe aimed to compare hemoglobin A1c (HbA1c), total and basal insulin doses, basal insulin injection frequencies, and body mass index (BMI) in children with type 1 diabetes mellitus (T1DM) who are receiving detemir and glargine as basal insulin in
BEREKET, ABDULLAH, DEMİRCİOĞLU, SERAP, GÜRAN, TÜLAY, HALİLOĞLU, BELMA   +3 more
core   +1 more source